Company Insights

OPK supplier relationships

Explore interactive graphBrowse insights index
OPK supplier relationship map

OPKO Health (OPK): Supplier and advisor roadmap for investors

Opko Health operates a dual business model: diagnostic services (primarily through BioReference laboratories) and pharmaceutical development/commercialization. The company monetizes via lab testing revenues, product sales and licensing, and milestone/collaboration payments while relying on a mix of in‑house manufacturing subsidiaries and third‑party manufacturers and advisors to execute clinical programs and commercial distribution. For investors evaluating counterparty exposure, the combination of strategic subsidiaries (EirGen, FineTech) and material third‑party spend highlights a hybrid contracting posture that balances outsourced execution with some vertical integration.
Discover more supplier intelligence at https://nullexposure.com/.

Why supplier relationships matter for OPKO's investment case

OPKO’s operating model is capital‑light on R&D commercialization but dependent operationally on outside manufacturing, large lab equipment and service suppliers, and financial/legal advisors. The 2024 Form 10‑K and subsequent press coverage collectively show four structural signals:

  • Contracting posture: OPKO relies on third‑party contract manufacturers and clinical service providers while maintaining manufacturing capability through subsidiaries — a deliberate mix that reduces single‑point manufacturing failure risk but preserves supplier dependency for scale. (Company disclosure, FY2024 10‑K.)
  • Concentration and spend profile: BioReference reported multi‑million dollar purchases from Danaher subsidiaries in 2024, including payments of $4.7M to Integrated DNA Technologies and $3.2M to Beckman Coulter, indicating mid‑to‑high single‑supplier exposure in diagnostic supplies and instruments. This places several suppliers in the $1M–$10M and $100k–$1M spend bands for 2024.
  • Criticality and maturity: OPKO’s subsidiaries (EirGen and FineTech) give the company internal capabilities for high‑potency API manufacture, reducing reliance on external API suppliers for certain assets and signaling a more mature internal supply capability relative to peers. (FY2024 10‑K.)
  • Advisory and capital relationships: The company uses top‑tier investment and legal advisors for strategic transactions and investor outreach, reflecting a standard governance posture for mid‑cap biotech/diagnostics. Recent terminations of share‑lending arrangements also show active treasury management. (FY2024 10‑K; press releases.)

If you track supplier risk or want to map OPKO’s dependency graph, start with their disclosed manufacturing and lab‑supply vendors and overlay advisory engagements. More detailed supplier profiles and exposure analytics are available at https://nullexposure.com/.

Catalog of disclosed supplier and advisor relationships

Itau Bank — lending relationship (FY2024)

OPKO’s FY2024 Form 10‑K lists a borrowing instrument with Itau Bank carrying a 5.50% interest and associated balances disclosed in the debt schedule, indicating a bilateral lending linkage for corporate financing needs. (OPKO Form 10‑K, FY2024.)

Bank of Chile — lending relationship (FY2024)

The same 10‑K shows debt with Bank of Chile at 6.60%, with labeled balances in the debt table, signaling OPKO’s use of international bank financing as part of its capital structure. (OPKO Form 10‑K, FY2024.)

EirGen — acquired specialty pharmaceutical subsidiary (FY2024)

OPKO acquired EirGen in 2015 and describes it as a specialty pharmaceutical company in Ireland focused on high‑potency, high‑barrier‑to‑entry products, positioning EirGen as an internal manufacturing/commercial supply source. (OPKO Form 10‑K, FY2024.)

FineTech Pharmaceutical, Ltd. — Israeli manufacturing subsidiary (FY2024)

FineTech is identified in the 10‑K as an Israeli‑based subsidiary that develops and manufactures high‑value, high‑potency specialty APIs, giving OPKO direct control over certain upstream manufacturing processes. (OPKO Form 10‑K, FY2024.)

Jefferies Capital Services, LLC — terminated share lending agreement (FY2024)

OPKO terminated its share lending agreement with Jefferies Capital Services on January 22, 2024, which reflects a change in OPKO’s securities lending or financing arrangements and reduced counterparty exposure under that program. (OPKO Form 10‑K, FY2024.)

Cowen — financial advisor on Sema4/Genedx transaction (FY2022)

In a company press release related to Sema4’s acquisition of GeneDx, Cowen is named as a financial advisor to OPKO on the transaction, demonstrating OPKO’s engagement of mid‑market advisors for strategic asset deals. (OPKO press release, 2022.)

J.P. Morgan — lead financial advisor on transaction (FY2022)

J.P. Morgan served as the lead financial advisor to OPKO in the same Sema4/GeneDx transaction, underscoring the use of global investment banks for major strategic transactions. (OPKO press release, 2022.)

Greenberg Traurig, P.A. — legal counsel (FY2022)

Greenberg Traurig is listed as OPKO’s legal counsel on the 2022 transaction press release, indicating reliance on established law firms for transaction and regulatory work. (OPKO press release, 2022.)

Jefferies (Jefferies Group) — investor events participation (FY2026)

OPKO announced management participation at the Jefferies Biotech on the Beach Summit (March 10–11, 2026), reflecting use of sell‑side platforms for investor outreach and capital markets visibility. (Sahm Capital news repost, Feb 2026.)

Alliance Advisors — investor relations contact (GlobeNewswire, FY2026)

OPKO’s investor materials for the 2026 J.P. Morgan Healthcare Conference list Alliance Advisors as the IR contact, illustrating the firm’s externalized investor relations support for major investor events. (GlobeNewswire press release, Jan 2026.)

Alliance Advisors — IR contact on earnings release (FY2026)

An OPKO press release announcing fourth quarter 2025 results also directs media and investor inquiries to Alliance Advisors contacts, confirming a standing IR relationship across corporate communications. (OPKO press release, Feb 2026.)

Alliance Advisors IR — event communication (FY2026)

A Sahm Capital notice similarly references Alliance Advisors in connection with Jefferies events, reinforcing that Alliance Advisors handles recurring investor communications for OPKO. (Sahm Capital news, Feb 2026.)

Entera Bio Ltd. — R&D collaboration for oral LA‑PTH (FY2026)

OPKO expanded a partnership with Entera Bio to co‑develop a first‑in‑class oral long‑acting PTH tablet for hypoparathyroidism, signaling dependence on external biotech collaborators to advance novel therapeutic formulations. (InsiderMonkey report on OPKO press release, Feb 4, 2026.)

Entera Bio — collaboration referenced on earnings call (2025Q4)

Management highlighted the Entera collaboration on the Q4 2025 earnings call, confirming the program’s active development status and its strategic place in OPKO’s pipeline. (OPKO 2025 Q4 earnings call, 2025Q4.)

Constraints and risk framing for operational due diligence

OPKO’s disclosures create a clear operational profile: active relationships with third‑party manufacturers and service providers, internal manufacturing through subsidiaries, and material spend with diagnostic suppliers. The company classifies many partnerships as ongoing and necessary for near‑term operations; it also discloses multi‑million dollar purchases from Danaher subsidiaries in 2024 (Beckman Coulter: $3.2M; Integrated DNA Technologies: $4.7M; Leica Microsystems: $0.3M), which is a concrete signal of supplier concentration in lab operations. Operational risk for procurement should be evaluated across three dimensions: contracting posture (mixed outsourcing/in‑house), concentration in diagnostic vendors, and the criticality of advisory relationships for capital and transaction execution.

If you want the full supplier map and exposure scoring for OPKO’s ecosystem, start your diligence with a focused supplier risk review and scenario modeling at https://nullexposure.com/.

Bottom line: what investors should watch

  • Supplier concentration in diagnostics and lab reagents is a tangible risk given multi‑million annual spend to a handful of vendors.
  • Subsidiaries EirGen and FineTech materially reduce upstream API risk but do not eliminate reliance on external contract manufacturers for some programs.
  • Advisory and financing counterparties are top‑tier, lowering execution risk on transactions, but changes in securities lending and bank borrowings alter treasury flexibility.

For investors and operators building counterparty models, OPKO’s disclosed relationships offer a pragmatic mix of integration and dependency — map them now and stress‑test cash flow and supply continuity scenarios at https://nullexposure.com/.